These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 9345383)

  • 1. Investigational drug therapies of treatment of multiple sclerosis.
    Panitch HS
    Mult Scler; 1996 Sep; 2(2):66-77. PubMed ID: 9345383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current and investigational therapies used to alter the course of disease in multiple sclerosis.
    Miller A
    South Med J; 1997 Apr; 90(4):367-75. PubMed ID: 9114824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Newer versus older treatments for relapsing-remitting multiple sclerosis.
    Weinstock-Guttman B; Cohen JA
    Drug Saf; 1996 Feb; 14(2):121-30. PubMed ID: 8852526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drugs in development for the treatment of multiple sclerosis: antigen non-specific therapies--an update.
    Donoghue S; Greenlees C
    Expert Opin Investig Drugs; 2000 Jan; 9(1):167-71. PubMed ID: 11060669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Editorial: Licensing and Use of New Therapies in MS: Where Are We Going?
    Hurwitz B
    Int MS J; 2005 Aug; 12(2):39-41. PubMed ID: 16417813
    [No Abstract]   [Full Text] [Related]  

  • 6. Nursing management of MS patients receiving interferon beta-1b therapy.
    Costello K; Conway K
    Rehabil Nurs; 1997; 22(2):62-6, 81. PubMed ID: 9110845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pathogenesis and treatment of multiple sclerosis (state of the art in 2000)].
    Zavalishin IA; Zhuchenko TD; Peresedova AV
    Vestn Ross Akad Med Nauk; 2001; (7):18-22. PubMed ID: 11523422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple sclerosis and interferon beta-1b, past, present and future.
    Horowski R
    Clin Neurol Neurosurg; 2002 Jul; 104(3):259-64. PubMed ID: 12127665
    [No Abstract]   [Full Text] [Related]  

  • 9. Disease-modifying drugs for relapsing-remitting multiple sclerosis and future directions for multiple sclerosis therapeutics.
    Rudick RA
    Arch Neurol; 1999 Sep; 56(9):1079-84. PubMed ID: 10488808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Time-course analysis of CD25 and HLA-DR expression on lymphocytes in interferon-beta 1b-treated multiple sclerosis patients.
    Ferrarini AM; Sivieri S; Buttarello M; Facchinetti A; Perini P; Gallo P
    Mult Scler; 1998 Jun; 4(3):174-7. PubMed ID: 9762669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging therapies in multiple sclerosis.
    Farrell R; Heaney D; Giovannoni G
    Expert Opin Emerg Drugs; 2005 Nov; 10(4):797-816. PubMed ID: 16262563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple sclerosis therapy. A practical guide.
    van Oosten BW; Truyen L; Barkhof F; Polman CH
    Drugs; 1995 Feb; 49(2):200-12. PubMed ID: 7729328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical efficacy and safety of long-term immunomodulating therapy with interferon beta].
    Demina TL; Khachanova NV; Davydovskaia MV; Popova NF; Gusev EI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(4):24-6. PubMed ID: 18567192
    [No Abstract]   [Full Text] [Related]  

  • 14. Neutralizing antibodies and the efficacy of interferon beta-1b in relapsing-remitting multiple sclerosis.
    Petkau J; White R
    Mult Scler; 1997 Dec; 3(6):402. PubMed ID: 9493643
    [No Abstract]   [Full Text] [Related]  

  • 15. [Side-effects of the treatment with disease modifying drugs in patients with multiple sclerosis: an analysis of register data in the Yaroslavl region].
    Spirin NN; Kasatkin DS; Stepanov IO; Shipova EG; Baranova NS
    Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(8):27-33. PubMed ID: 23096035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis (INCOMIN Trial) II: analysis of MRI responses to treatment and correlation with Nab.
    Barbero P; Bergui M; Versino E; Ricci A; Zhong JJ; Ferrero B; Clerico M; Pipieri A; Verdun E; Giordano L; Durelli L;
    Mult Scler; 2006 Feb; 12(1):72-6. PubMed ID: 16459722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon beta treatment for multiple sclerosis: persisting questions.
    Goodkin DE
    Mult Scler; 1996 Jul; 1(6):321-4. PubMed ID: 9345408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current disease-modifying therapies in multiple sclerosis.
    Kieseier BC; Hartung HP
    Semin Neurol; 2003 Jun; 23(2):133-46. PubMed ID: 12894379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Therapy of multiple sclerosis].
    Simó M
    Neuropsychopharmacol Hung; 2009 Mar; 11(1):23-6. PubMed ID: 19731815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current developments in neurology, Part I: Advances in the pharmacotherapy of headache, epilepsy, and multiple sclerosis.
    Gidal BE; Wagner ML; Privitera MD; Dalmady-Israel C; Crismon ML; Fagan SC; Graves NM
    Ann Pharmacother; 1996 Nov; 30(11):1272-6. PubMed ID: 8913410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.